Butea monosperma for Health & Longevity - Quick Reference Sheet

Butea monosperma for Health & Longevity

Created on 10/14/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 3.1 – Audit

Butea monosperma is a South Asian medicinal tree whose bark, flower, and leaf compounds are studied for bone preservation, blood sugar and fat control, and inflammation reduction. Standalone longevity benefits are speculative, resting on rodent and cell studies; human trials only tested herb combinations for kidney stones or parasites. Given low oral absorption, rodent seed organ toxicity, and flower fertility risks, extracts remain early laboratory candidates. (Full Review)

Protocol

Investigational osteogenic vs. Ayurvedic dosing
~1.6 mg/kg daily (~110 mg daily) bark isoflavones
Rodent bone translation; Ayurvedic trials give 500 mg Palasha Kshara three times daily
Time of day and meal timing
After fat-containing morning and midday meals
Aids isoflavone absorption and avoids evening thermogenic sleep disruption
Single vs. split dosing
Split dosing two or three times daily
Preferred because medicarpin (17%) and cladrin (7% to 19%) absorption drops at higher doses
Time to effect
Intestinal parasite clearance in giardiasis
15 days
Human combination trial with Piper longum (72 percentage points higher clearance vs. placebo)
Urinary stone symptom relief and clearance
8 weeks
Human combination trial with Ashmarihara Kwatha (14.21 percentage points higher stone-size reduction)
Bone density preservation and osteogenesis
6–12 weeks
Rodent BMD and lipid improvements only (no human trials)

Benefits

Contraindications
  • Pregnant and lactating women
  • Men and women actively trying to conceive
  • Individuals with renal impairment, hypoalbuminemia, or anemia
  • Individuals with hormone-sensitive malignancies
Key Interactions
  • Antidiabetic prescription medications (metformin, glimepiride, insulin) (caution, theoretical)
  • Hepatic CYP substrates (warfarin, phenytoin, theophylline) (monitor, theoretical, 3–4 h stagger)
  • Estrogen-receptor modulators and hormones (raloxifene, tamoxifen, estradiol) (monitor, theoretical)
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen, aspirin) and acetaminophen (avoid with seeds / caution with bark or flowers, theoretical)
  • Glucose-lowering supplements (berberine, alpha-lipoic acid, Gymnema sylvestre) (monitor, theoretical)
  • Phytoestrogenic supplements (soy isoflavones, red clover, Pueraria mirifica) (caution, theoretical)
  • Prolonged fasting and ketogenic diets (monitor, theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Nephrotoxicity, hypoalbuminemia, hyperlipidemia, and anemia from seed preparations; male spermatogenic suppression and testicular impairment; female implantation failure and uterotrophic modulation; gastrointestinal mucosal disruption and splenic hypocellularity

Monitoring

Marker Target Why
Serum Albumin and Total Protein Albumin: 3.5–5.0 g/dL; Total Protein: 6.0–8.3 g/dL (standard reference range) Safety check: detects seed-associated hypoalbuminemia and hypoproteinemia
Serum Creatinine and eGFR Creatinine: 0.6–1.2 mg/dL; eGFR: ≥90 mL/min/1.73 m² (standard reference range) Safety check: screens for palasonin-associated renal tubular or glomerular injury
Hemoglobin and Hematocrit Hemoglobin: 13.5–17.5 g/dL (men), 12.0–15.5 g/dL (women); Hematocrit: 36%–50% (standard reference range) Safety check: monitors for seed-associated reductions in red blood cell indices
Fasting Blood Glucose and Triglycerides Glucose: 70–99 mg/dL; Triglycerides: <150 mg/dL (standard reference range) Safety check and expected-change marker: tracks glycemic and lipid responses or seed-induced hypertriglyceridemia
Lumbar Spine and Hip BMD (DXA) and Serum CTX-I No established target; stabilization or increase in BMD and reduction in CTX-I from individual baseline Expected-change marker: evaluates osteogenic and antiresorptive response to stem bark fractions

Cadence: Baseline, 4 and 12 weeks after initiation, and every 6 to 12 months thereafter during cyclic supplementation (with DXA repeated every 12 to 24 months); discontinuation threshold if eGFR drops >15% or albumin (<3.5 g/dL) or hemoglobin falls below normal.

Qualitative Assessment

  • Joint comfort and morning stiffness: Reductions in activity-related joint discomfort when using flower extracts
  • Gastrointestinal tolerance: Stool frequency, abdominal comfort, and absence of nausea after postprandial dosing
  • Daytime energy: Shifts in energy, stress resilience, or warmth